The details behind AstraZeneca's $320 million acquisition of groundbreaking cancer treatment firm
-$320 million acquisition accelerates cancer franchise-Potential to unlock new ways to fight cancer-Deal expected to close in first quarter of 2023Pharma group AstraZeneca (AZN) is acquiring next generation T-cell receptor therapies...
29 November 2022